BioPharma Resources

Drug Trial Radar · NCT07494409

A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia

A Phase 3, Multi-center, Randomized, Open-Label, Active-Controlled, Efficacy and Safety Study of AND017 to Treat Anemia in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Oct 31, 2025

Primary completion

Feb 20, 2027

Study completion Oct 30, 2027

Sponsor

Lead sponsor
Kind Pharmaceuticals LLCIndustry
Sponsor type
Industry
First posted
Mar 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase III, randomized, open-label, active-controlled study to evaluate the safety and efficacy of AND017 in anemic patients with End-Stage-Kidney-Disease (ESKD)

Conditions

  • Anemia Due to Chronic Kidney Disease

Interventions

  • AND017 capsulesDrug

    AND017 capsules administered orally with a starting dose of 10 mg TIW

  • ESADrug

    ESA injection and dose based on package insert and local practice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the efficacy of AND017 compared with the active control in maintaining Hb levels in anemic patients with ESKDTime frame: From Week 23 to Week 27

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan Univeristy Zhongshan Hospital

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.